11:33:04 EDT Fri 24 Mar 2023
Enter Symbol
or Name

Cybin Inc
Symbol CYBN
Shares Issued 185,600,974
Recent Sedar Documents

Cybin to hold R&D day on Feb. 28

2023-01-26 10:59 ET - News Release

Ms. Leah Gibson reports


Cybin Inc. will host a virtual R&D (research and development) day on Tuesday, Feb. 28, 2023, from 10 a.m. ET to 11:30 a.m. ET.

The event, which will be hosted by Cybin's leadership team, will provide a progress update on the company's development pipeline of differentiated psychedelic-based therapeutics, including CYB003 and CYB004. Specifically, the company plans to provide an interim readout from the continuing phase 1/2a study evaluating CYB003, an update from the continuing phase 1 exploratory CYB004-E trial evaluating IV N,N-dimethyltryptamine and a review of its clinical development program evaluating CYB004. Cybin is evaluating CYB003 for the treatment of major depressive disorder and CYB004 is being evaluated for the treatment of generalized anxiety disorder.

A Q&A (question and answer) session for the investment community will follow the prepared remarks. The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page following the event.

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

We seek Safe Harbor.

© 2023 Canjex Publishing Ltd. All rights reserved.